Hypersplenism Clinical Trial
Official title:
Comparative Study of Microwave Ablation and Partial Splenic Embolization in the Management of Hypersplenism
The aim of this study is to compare microwave thermal coagulation and partial splenic
embolization in the management of hypersplenism in patients with cirrhosis.
This study will be conducted on 40 patients with liver cirrhosis associated with
splenomegaly and hypersplenism. The study will be done at the National Hepatology and
Tropical Medicine Research Institute.
Liver cirrhosis or portal hypertension is frequently associated with congestive splenomegaly
resulting in hypersplenism.
Hypersplenism can be defined as anemia, leukopenia, thrombocytopenia, or a combination of
these resulting from excessive, splenic sequestration or pooling of blood cells, usually
associated with clinical splenomegaly and always ameliorated by splenectomy.
Partial splenic embolization (PSE), which was first performed by Spigos et al in 1979, has
been considered first-line therapy for hypersplenism in many institutions, and has been
proposed as an effective alternative to splenectomy for improving peripheral blood cell
counts. However, PSE is associated with many complications, including intermittent fever,
abdominal pain, nausea, vomiting, post-embolization syndrome, splenic abscess, splenic
rupture, pneumonia, refractory ascites, pleural effusion and gastrointestinal bleeding. To
ensure a sustained and long-term increase in platelet and leucocytic counts, the splenic
infarction rate needs to be greater than 50%. Thus, severe complications can ensue.
Thermal ablation methods using different energy sources, such as radiofrequency (RF),
microwave (MW), or laser, were developed rapidly as minimally invasive techniques for the
eradication of local tumor tissue within solid organs. There have been reports of the use of
radiofrequency to ablate normal spleen, splenic injury, and splenomegaly.
Radiofrequency Ablation (RFA) had comparable efficacy and a better safety than PSE in the
treatment of hypersplenism in patients with post hepatitis c cirrhosis.
MW ablation performed either laparoscopically or percutaneously is a safe, effective, and
minimally invasive technique for the management of hypersplenism in patients with liver
cirrhosis. It may significantly increase platelet count and white blood cells (WBC) count
and improve hepatic blood supply with fewer complications. Ablating more than 40% of the
splenic parenchyma may yield better long term results. This method may provide a new and
promising minimally invasive alternative for treating hypersplenism.
The aim of this study is to compare microwave thermal coagulation and partial splenic
embolization in the management of hypersplenism in patients with cirrhosis.
This study will be conducted on 40 patients with liver cirrhosis associated with
splenomegaly and hypersplenism. The study will be done at the National Hepatology and
Tropical Medicine Research Institute.
All patients will be subjected to thorough history taking, full clinical, lab,
ultrasound/doppler, and upper endoscopic examination. Diagnosis has been based on peripheral
blood count and confirmed with bone marrow examination.
Preoperative antibiotics will be given and correction of bleeding tendency with plasma and
platelet transfusion will be done as required to get a prothrombin concentration more than
65% and platelet count more than 100,000.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05055713 -
A Randomized Controlled Study on the Treatment of Cirrhosis Combined With Hypersplenism
|
N/A | |
Not yet recruiting |
NCT03269877 -
Hypersplenism in Patients With Liver Cirrhosis and Portal Hypertension
|
N/A | |
Completed |
NCT05446116 -
Transfemoral Versus Transradial Partial Splenic Artery Embolization in Patients With Hypersplenism
|
N/A | |
Recruiting |
NCT04692805 -
EUS-guided PSE in Combination With EUS-guided Treatment of Varices for Patients With Portal Hypertension
|
N/A | |
Completed |
NCT00605657 -
Valproic Acid (Depakote[Registered Trademark]) to Treat Autoimmune Lymphoproliferative Syndrome (ALPS)
|
Phase 1/Phase 2 |